Praxis Precision Medicines (PRAX): One of the Best Upside Stocks [Yahoo! Finance]
FDA Moves Ulixacaltamide Forward As Praxis Valuation Gap Draws Focus [Yahoo! Finance]
Praxis Precision Medicines (PRAX) had its "buy" rating reaffirmed by Deutsche Bank Aktiengesellschaft.
Praxis Precision Medicines (PRAX) had its "buy" rating reaffirmed by Needham & Company LLC. They now have a $510.00 price target on the stock.
Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide HCl in Patients with Essential Tremor